Skip to main content

Degree of Adherence in Chronic Diseases Inversely Correlates with Healthcare Costs

May/June 2011, Vol 4, No 3 - Conference Highlights AMCP

One successful strategy for employers and health plans wishing to cut spending on their employees or members with chronic diseases is to implement ways of encouraging strong medication adherence. In a poster presentation led by Patty M. Fong, PharmD, researchers from American Health Care plan, Rocklin, CA, have demonstrated that the degree of a patient’s medication adherence inversely correlates with the amount of total healthcare dollars spent on that patient.

Using pharmacy claim data, the team evaluated the correlation between several levels of medication adherence and the amount of medical costs in patients with 1 of 3 chronic diseases over a 12-month period. They divided 4999 patients with hypertension (N = 2610), dyslipidemia (N = 1669), or diabetes (N = 720) into 1 of 5 groups according to the level of their medication adherence, based on medication possession ratio (MPR).

Cost measures included prescription costs, medical costs, and total healthcare costs. In each disease state, >75% of patients had an MPR between 80% and 100%. Greater medication adherence across all 3 disease states was associated with significantly lower medical and total healthcare costs, even as total prescription costs were highest among the most medicationadherent patients.

The strongest correlation was found in patients with dyslipidemia, in which annual prescription costs ranged from $1259 for the least adherent patients to $2252 for the most adherent. In contrast, annual medical cost was $2869 for the most adherent patients compared with $12,393 for the least adherent patients, amounting to total annual healthcare costs of $5121 for the most adherent compared with $13,653 for the least adherent patients.

The same inverse trend was seen in the patients with hypertension or diabetes; however, in the case of diabetes, the most adherent patients also had the highest total healthcare costs—$11,950—of all patients with an MPR between 80% and 100%, which “makes patients with diabetes part of the 5% of the total population who contribute to 75% of healthcare costs,” Dr Fong and colleagues observed.

Related Items
Can Technologic Innovations and Formulary Considerations Improve Healthcare Outcomes?
Charles Bankhead
June 2018 Vol 11, No 4 published on June 25, 2018 in Conference Highlights AMCP
AMCP Nexus 2017 Highlights
December 2017 Vol 10, No 9 published on January 3, 2018 in Conference Highlights AMCP
Challenges and Opportunities in Managing Type 2 Diabetes
Laura Morgan
June 2017 Vol 10, No 4 published on June 22, 2017 in Conference Highlights AMCP
Payers’ Perspective: Incorporating Real-World Evidence in Patient Care
Lilly Ostrovsky
April 2017 Vol 10, No 2 published on April 18, 2017 in Conference Correspondent, Conference Highlights AMCP
Implications of Real-World Data and Pharmacoeconomics for Managed Care
Lilly Ostrovsky
May 2016 Vol 9, No 3 published on May 25, 2016 in Conference Highlights AMCP
Last modified: August 30, 2021